SGLT2 inhibitors may reduce risk, progression of CKD, AKI regardless of diabetes status
Click Here to Manage Email Alerts
ORLANDO — SGLT2 inhibitors reduce the risk and progression of chronic kidney disease and AKI regardless of diabetes status, according to data presented at ASN Kidney Week.
“In the studied populations, SGLT2 inhibitors safely reduce the risk of kidney disease progression and acute kidney injury irrespective of diabetes status. In the CKD trials, these benefits do not appear to be modified by kidney diagnosis. The absolute benefits clearly exceed harm in patients with CKD irrespective of diabetes status,” Natalie Staplin, PhD, of the Medical Research Council Population Health Research Unit at the University of Oxford, said, here.
Staplin presented meta-analysis data of 13 large, placebo-controlled randomized clinical trials that have studied SGLT2 inhibitors. In total, 90,413 patients were studied, of which approximately 15,953 patients did not have diabetes. Each trial had more than 500 patients per arm.
The key outcome was kidney disease progression, which researchers defined as a sustained 50% or more decline in eGFR from randomization, start of maintenance dialysis or transplantation, development of end-stage kidney disease or death from kidney failure. Other outcomes included AKI, hospitalization for heart failure or cardiovascular death, non-cardiovascular death, ketoacidosis and amputation.
Researchers found 1,759 patients with diabetes and 489 patients without diabetes had a kidney disease progression. Overall, 940 patients had diabetic kidney disease, 130 with hypertensive/ischemic disease, 230 with glomerular disease and 110 with other/unknown causes showed kidney disease progression. She said SGLT2 inhibitors reduced the risk of progression of kidney disease by 37% and AKI by 23%.
“The relative risks associated with allocation to SLGT2 inhibitor was similar for patients with and without diabetes with no evidence of heterogeneity by diabetes status,” Staplin said.
Collapse
Staplin N, et al. FR-OR69. Presented at: ASN Kidney Week; Nov. 3-6, 2022; Orlando (hybrid meeting).
Read more about
Click Here to Manage Email Alerts